What Is AI Regulatory Writing in Clinical Research?

Every drug that reaches a patient passes through an invisible infrastructure of documents. Before a single participant is enrolled, a clinical trial protocol defines what will happen, to whom, and why. Before an investigator recruits a participant, an informed consent form must explain risks in plain language. After the last data point is locked, a clinical study report of several hundred to several thousand pages must reconstruct the entire trial for a regulatory reviewer who was not in the room. These documents are not administrative formalities. They are the legal and scientific record on which drug approvals rest.

For decades, producing them has been almost entirely a manual endeavor, dependent on experienced medical and regulatory writers who synthesize clinical data, align language across documents, and navigate a dense web of agency expectations. Now, large language models (LLMs) and natural language processing (NLP) are entering that workflow. AI regulatory writing is not a single technology or a single tool. It is a category of applications designed to assist or automate the drafting, review, and consistency-checking of the documents that govern clinical trial conduct and support regulatory submissions.

This article explains what regulatory writing in clinical research actually entails, what AI is beginning to do within it, where the evidence sits, and where the risks remain real.

Why Regulatory Writing Has Always Been Difficult

Regulatory writing sits at the intersection of clinical science, statistics, and legal language. A regulatory writer's output must be accurate to the protocol, consistent with other trial documents, compliant with agency formatting requirements, and written at a level of clarity that a regulatory reviewer can follow without ambiguity.

The documents involved span the entire trial lifecycle. ICH E6(R3), the foundational Good Clinical Practice guideline adopted in January 2025 and effective from July 2025, defines the sponsor's responsibilities for producing essential trial documentation including the protocol, the investigator's brochure (IB), and the clinical study report (CSR)^[1]. The CSR's structure and content requirements are governed by ICH E3, which provides the internationally harmonized format accepted by regulatory authorities across ICH regions^[2]. Protocol formatting itself has been further standardized through ICH M11, which introduced a clinical electronic structured harmonised protocol template to address inconsistencies in how sponsors prepare and submit protocols^[3]. For informed consent forms (ICFs) in the U.S., the content requirements are set out in 21 CFR Part 50^[4]. These guidelines collectively define the regulatory writing landscape.

The volume and complexity of this work has grown substantially. A 2024 study published in Therapeutic Innovation & Regulatory Science by Getz and colleagues at the Tufts Center for the Study of Drug Development (CSDD), drawing on data from 950 protocols and 2,188 amendments collected from 16 pharmaceutical companies and CROs, found that the prevalence of protocols with at least one substantial amendment in Phases I-IV has increased from 57% to 76% since 2015^[5]. The mean number of amendments per protocol rose 60%, from 2.1 to 3.3^[5]. Earlier Tufts CSDD benchmark research found that the median direct cost to implement a substantial amendment runs from $141,000 for Phase II protocols to $535,000 for Phase III^[6]. A 2023 Tufts CSDD analysis reported in Applied Clinical Trials found that the average time from identifying the need for an amendment to the last ethics review board approval has nearly tripled over the past decade, now averaging 260 days^[7].

That time pressure, combined with the sheer volume of documentation required, is what makes regulatory writing one of the most resource-constrained functions in clinical drug development.

What AI Regulatory Writing Actually Means

AI regulatory writing refers to the use of machine learning, NLP, and generative AI to assist in producing, reviewing, or quality-checking regulatory documents in the clinical research context. The term covers a spectrum of applications, from simple template population to fully generative first-draft production.

The Document Types in Scope

Understanding which documents AI touches requires understanding what each one does.

The Clinical Trial Protocol is the operational blueprint of a study. It specifies objectives, endpoints, eligibility criteria, randomization procedures, dosing, assessments, statistical methods, and safety monitoring plans. ICH M11 provides a harmonized structured template for protocol development to support interoperability across regulatory authorities^[3]. Protocol errors and design inconsistencies are among the leading causes of amendments; and therefore among the clearest targets for AI-assisted drafting.

The Investigator's Brochure compiles all preclinical and clinical data on the investigational product, serving as the primary reference for site investigators and ethics committees. ICH E6(R3) requires the IB to be updated at least annually, or more frequently when significant new safety information is available^[1].

The Informed Consent Form must satisfy the content requirements of 21 CFR Part 50 in the U.S.^[4], along with applicable EU Clinical Trials Regulation requirements for trials operating in Europe. The ICF must communicate risks, benefits, procedures, and participant rights in plain language accessible to a layperson; while simultaneously satisfying the legal and institutional review requirements that vary across countries and ethics committees.

The Clinical Study Report is the comprehensive account of a completed trial's design, conduct, and results. ICH E3 governs its structure and content, and the document serves as the primary scientific and statistical record submitted to regulators seeking drug approval^[2]. Despite efforts to streamline CSR production through initiatives like TransCelerate's modernized CSR template, the time required to produce a CSR from receipt of final tables, figures, and listings to document approval has remained between 6 and 15 weeks across major pharmaceutical companies surveyed in recent years^[8].

What AI Systems Do Within These Documents

At the current state of the field, AI applications in regulatory writing generally fall into three functional categories.

Automated first-draft generation. LLMs prompted on regulatory guidance documents, prior protocols, and trial-specific inputs can produce structured initial drafts of documents or document sections. Research published in 2025 demonstrated that retrieval-augmented generation (RAG) approaches; which ground LLM outputs in specific source documents rather than general training data; substantially improve compliance with regulatory formatting rules^[9]. A study comparing an LLM-driven ICF generation system, InformGen, against a baseline GPT-4o model found that the specialized system achieved near-100% compliance with 18 core FDA regulatory rules for ICF structure, outperforming the unoptimized model by up to 30 percentage points^[9]. These results come from controlled research conditions and represent promising initial evidence, not validated production performance across diverse sponsors, countries, and ethics committees.

Cross-document consistency checking. One of the most persistent problems in regulatory writing is inconsistency across the document suite. A change in an endpoint definition in the protocol that is not propagated to the SAP, or a safety signal described differently in the IB and the DSUR, creates quality issues that reviewers will flag and writers will have to resolve under deadline. NLP systems designed to extract and compare specific entities (endpoints, dosing parameters, eligibility criteria, statistical assumptions) across document versions can identify these discrepancies more reliably than manual review alone.

Data-to-text generation. Clinical study reports require the translation of statistical outputs, tables, and listings into narrative prose. Natural language generation systems have been applied to this task, converting structured clinical data into compliant narrative descriptions of results, adverse event profiles, and safety summaries^[10]. This is a more bounded application of AI than full document drafting, and one where quality control is more tractable because the source data is structured and verifiable.

The Research Landscape

A 2025 scoping review published in npj Digital Medicine analyzed 142 studies on AI applications in clinical trial risk assessment published between 2013 and 2024, covering safety, efficacy, and operational risk prediction^[11]. The review found that LLMs have seen a surge in applications, appearing in 7 of 33 studies from 2023, and noted that while some models achieve high performance on specific benchmarks (AUROC up to 96%), challenges including selection bias and limited prospective studies remain barriers to broad deployment^[11].

On the clinical document generation side, a 2025 npj Digital Medicine policy framework paper argued that AI-powered trial design tools, constrained to established best practices, could help avoid common protocol flaws and improve consistency across design elements^[12]. The paper distinguishes near-term applications from more speculative visions, emphasizing that domain experts should retain central roles in training data curation, model validation, and oversight.

A 2024 article in Health Technology examining AI-powered clinical trials identified accountability, transparency, and regulatory uncertainty as primary implementation challenges, alongside data privacy risks in AI-driven workflows^[13].

The hallucination problem deserves direct attention. A 2025 framework published in npj Digital Medicine examining LLM performance in clinical text summarization found a 1.47% hallucination rate and a 3.45% omission rate across 12,999 clinician-annotated sentences in experimental configurations^[14]. These rates apply to the summarization task studied and should not be generalized indiscriminately to all regulatory document contexts. But the directional point stands: in a regulatory document, even a low hallucination rate carries real consequences. A fabricated dosing parameter, a misstated eligibility criterion, or an incorrect adverse event count can compromise a submission's integrity. This is why every serious implementation of AI in regulatory writing currently relies on a human-in-the-loop review model^[15].

Operational Implications for Regulatory Teams

The table below maps document type to current AI use cases, the primary risk in each, and the human review requirement that applies.

Protocol Development and Amendment Management

AI assistance is most commonly introduced at the protocol drafting stage, where LLMs can populate standard sections from structured trial parameters, aligned to ICH M11 templates^[3]. The efficiency gains are genuine: manual protocol authoring for a Phase II or Phase III study typically requires weeks of drafting, cross-functional review, and iterative revision. AI-assisted systems can compress first-draft production substantially, allowing medical writers and clinical scientists to focus on the decisions that require human judgment: endpoint selection, risk-benefit framing, eligibility criteria that are neither so restrictive as to impede enrollment nor so broad as to produce a noisy dataset.

However, protocol quality problems are not primarily a writing problem. The Tufts CSDD data makes clear that the leading causes of amendments in the 2024 study included regulatory agency requests and changes to the study strategy, not simply drafting errors^[5]. AI systems that accelerate drafting without improving the underlying clinical and statistical design decisions will reduce document production time while leaving amendment rates largely unchanged.

ICF Development and Global Trial Complexity

AI-assisted ICF generation presents a specific opportunity because ICFs are highly structured, reference-dependent documents with well-defined regulatory requirements. The content rules under 21 CFR Part 50 and equivalent EU CTR provisions are finite and specifiable, making compliance checking by AI systems trained on those rules tractable^[4],[9]. For global trials operating in 20 or more countries, AI can help identify which elements of a master ICF require country-specific modification. What the expert judgment about the specific modifications should be remains a human function.

CSR Automation

The CSR is where generative AI has attracted the most industry attention, and also where the risks of automated drafting are highest. The document can run to thousands of pages. ICH E3 requires comprehensive coverage of study design, conduct, and results, and any factual inaccuracy in a CSR submitted to the FDA or EMA is a regulatory and legal problem^[2]. Current applied work uses AI primarily for the most structured, data-driven sections where natural language generation from tabulated data is less likely to introduce factual error^[10]. Narrative synthesis sections, which require clinical judgment to interpret, are generally treated as requiring more intensive human authoring, with AI in a supporting rather than generative role.

Regulatory and Documentation Considerations

The guidance frameworks governing AI use in clinical document production are still forming, but several established requirements already apply.

ICH E6(R3) was adopted under Step 4 on January 6, 2025, and came into effect in EU jurisdictions on July 23, 2025; the FDA made the final guidance available in September 2025^[1]. The revised guideline introduces a quality-by-design framework with strong emphasis on traceability of decisions, clarity of documentation, and proportionate risk-based approaches throughout the trial lifecycle^[1]. For regulatory writing, ICH E6(R3) requires that documents reflect trial-specific risks and mitigations, that data management and analysis decisions are traceable in the written record, and that documentation is complete and clear. These are documentation quality requirements that apply regardless of whether AI is involved in the drafting process. In that sense, AI-assisted workflows must actively support; not erode; the traceability and consistency that E6(R3) demands.

FDA draft guidance on AI in drug development, published in 2025, provides recommendations on the use of AI to produce information or data intended to support regulatory decision-making regarding safety, effectiveness, or quality for drugs^[16]. It was informed by over 800 external comments on the FDA's 2023 AI/ML discussion paper and by CDER's experience with more than 500 submissions containing AI components from 2016 to 2023^[16]. The guidance establishes a risk-based credibility assessment framework: the level of validation and oversight required for an AI application scales with the degree to which that application directly influences regulatory decision-making. AI tools used to assist internal document drafting; without their outputs constituting the direct evidence submitted for marketing authorization; sit at a different risk level than AI tools generating the primary safety or efficacy data itself. Sponsors should assess each use case against these criteria, rather than assuming a single governance posture covers all AI-assisted regulatory writing.

The EU AI Act, adopted in 2024 and with enforcement phasing in through 2026, applies to AI systems deployed by EU-based providers and to non-EU providers whose system outputs are used in the EU^[17]. It takes a risk-proportionate approach, establishing different requirements based on risk classification. The general principles around transparency, human oversight, and documentation of AI system behavior apply broadly, though the precise classification of a regulatory writing tool under the Act requires legal analysis specific to the tool's role and context of use.

What AI Cannot Replace in Regulatory Writing

The efficiency case for AI regulatory writing is genuine. Document automation compresses first-draft production, reduces consistency errors at scale, and allows medical writers to concentrate on the scientific and strategic judgments that AI cannot make.

What AI systems currently cannot do well is reason about context they were not given. A regulatory writer reading a draft protocol who has worked in the therapeutic area for fifteen years will notice that an eligibility criterion is likely to generate unworkable enrollment rates at sites they know. An LLM working from a template and trial parameters will not. Similarly, AI cannot interpret ambiguous regulatory guidance the way an experienced regulatory affairs professional can, drawing on knowledge of how a specific agency division has applied a requirement in prior review cycles.

A second risk is automation bias. Research published across human factors engineering and human-computer interaction literature consistently shows that humans reviewing AI-generated outputs tend to over-rely on automated recommendations, missing errors they would catch in content they authored themselves^[18]. A 2025 randomized experiment with 2,784 participants found that individuals exposed to AI suggestions performed significantly worse at error detection on subsequent tasks, and that positive first impressions of an AI system disproportionately influenced how users evaluated its later outputs^[19]. In a regulatory document review context, this is not a hypothetical failure mode. It is a documented cognitive mechanism with real implications for how review protocols should be structured.

These risks are manageable with well-designed human-in-the-loop workflows, prompt and version governance, and validation packages for AI tools used in regulated contexts. But they do not disappear simply because a human reviewer is nominally in the loop.

How Kitsa Fits Into This Problem

KScribe, Kitsa's AI-powered regulatory document generation product, is built specifically for the clinical regulatory writing workflow. It addresses the document types where the gap between current capability and actual output quality is most acute: protocols, ICFs, IBs, DSURs, and CSRs. Cross-document consistency is a core architectural requirement within KScribe, not a post-hoc quality check: when a design element changes in the protocol, the system flags required updates across connected documents, supporting the traceability obligations that ICH E6(R3) demands. Source documents are ingested and versioned, reviewer workflows are structured to counteract the automation bias risk, and the system operates within Kitsa's SOC2, HIPAA, and ISO27001 compliance frameworks, which matters when the inputs include proprietary clinical trial data and the outputs feed directly into regulatory submissions.

Frequently Asked Questions

References

You Might Also Like